Trial reportPsychopharmacology2009
Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study.
Trial report in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 30 citations in OpenAlex.
- Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2014Trial
- Improved planning abilities in binge eating.PloS one · 2014Trial
- Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.The international journal of neuropsychopharmacology · 2013Trial
- Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.International journal of geriatric psychiatry · 2012Trial
- Choline Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population.Geriatrics (Basel, Switzerland) · 2025Review
- The attention-emotion interaction in healthy female participants on oral contraceptives during 1-week escitalopram intake.Frontiers in neuroscience · 2022Article
- Goal Directed and Self-Control Systems in Bulimia Nervosa: An fMRI Study.EBioMedicine · 2018Article
- Preference for Safe Over Risky Options in Binge Eating.Frontiers in behavioral neuroscience · 2016Article
- A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression.Therapeutic advances in psychopharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe role of serotonin (5-HT) in attention is not fully understood yet.
objectiveWe aimed to investigate whether attention is modulated after treatment with escitalopram, a selective serotonin reuptake inhibitor (SSRI).
methodsWe administered 10 mg of escitalopram to 20 healthy subjects in a placebo-controlled, double-blind cross-over design for 1 day or to another 20 participants for a period of 7 days. Attention was assessed at time of plasma peak escitalopram concentration using the computerised Attention Network Test (ANT), which is a combined flanker and cued reaction time task.
resultsThe results showed differential effects of serotonergic manipulation on attention depending on sequence of intake. For the acute treatment, we found significant differences between escitalopram and placebo for all warning conditions dependent of sequence of intake: participants receiving escitalopram as first treatment showed significant slower reaction times in all warning conditions as compared with placebo while participants receiving escitalopram as second treatment showed significant faster reaction times as compared with placebo. For the sub-chronic treatment, we found significant differences between escitalopram and placebo depending on sequence of intake, but only for the flanker condition: participants receiving escitalopram first had significant slower reaction times in incongruent trials with escitalopram as compared with placebo while participants starting with placebo had significant shorter reaction times in incongruent trials with escitalopram.
conclusionsThus, the results showed a differential effect of escitalopram in cognition, especially in attention, and are discussed with regard to an interaction between serotonin and familiarity with the attention test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.